Arrowhead Pharmaceuticals Inc (ARWR)

Debt-to-capital ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	393,183	—	—	—	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	185,444	330,547	483,794	160,407	271,343	364,830	446,772	377,039	398,520	453,927	452,266	372,560	408,822	436,890	445,549	454,472	461,779	493,140	494,119	500,084
Debt-to-capital ratio		0.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

September 30, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $393,183K ÷ ($393,183K + $185,444K)
= 0.68

The debt-to-capital ratio for Arrowhead Pharmaceuticals Inc has been relatively stable at 0.00 for the majority of the periods listed. However, there is a significant increase to 0.68 as of Sep 30, 2024. This suggests that the company's level of debt in relation to its total capital has risen sharply in the most recent period, indicating a potential increase in financial leverage. It would be important for stakeholders to further investigate this sudden change and assess the implications for the company's financial health and risk profile.